3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
Dermatologic
3
Gastrointestinal
2
Breast
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
63
Nivolumab
44
atezolizumab
14
Docetaxel
10
Cyclophosphamide
10
Paclitaxel
9
Magnetic Resonance Spectroscopy
9
Ipilimumab
9
avelumab
8
Specimen Handling
8
durvalumab
7
Radiosurgery
7
Cetuximab
7
spartalizumab
6
Radiotherapy
6
Immune Checkpoint Inhibitors
6
Interleukin-2
5
Carboplatin
5
fludarabine
4
cabozantinib
4
Trastuzumab
4
Sunitinib
4
Psychiatric Rehabilitation
4
Pemetrexed
4
Oxaliplatin
4
Fluorodeoxyglucose F18
4
Everolimus
4
Cisplatin
4
Capecitabine
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
bempegaldesleukin
×
Thoracic
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts